KLI

Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

Metadata Downloads
Abstract
We conducted a phase II clinical trial to develop an autologous EBV-specific T cell product (baltaleucel T) for advanced, relapsed ENKTL. Among 47 patients who provided whole blood starting material for manufacturing the product, 15 patients received a median of 4 doses of baltaleucel T. Thirty-two (68%) patients did not receive baltaleucel-T due to manufacturing failure, rapid disease progression, and death. Of the 15 patients, 10 patients had measurable disease at baseline (salvage cohort), and 5 patients had no disease at baseline assessment (adjuvant cohort). In the 15 patients, the median follow-up duration was 10.2 months (range 2.0-23.5 months), median progression-free survival (PFS) was 3.9 months, and the median overall survival (OS) was not reached. Patients in the salvage cohort achieved a 30% complete response (CR) and a 50% overall response rate (ORR). In the adjuvant cohort, disease progression was reported in three patients and two patients did not relapse during study follow-up. When we compared survival outcomes of seven responders and eight non-responders, the PFS (P = 0.001) and OS (P = 0.014) of responders proved statistically superior to that of non-responders. Baltaleucel-T was well tolerated. We have performed a phase II clinical trial of autologous EBV-specific T cell treatment (baltaleucel-T) in R/R ENKTL. Autologous EBV-specific T cells were well tolerated and demonstrated single-agent activity in R/R ENTKL.
Author(s)
강혜진김석진김원석김진석서철원윤덕현윤상은이용표조재철Arnaud JaccardCatherine M BollardCliona M RooneyDaniel Y LeeEmmanuel BachyEric D JacobsenFelipe SuarezHelen E HeslopHun Ju LeeJia RuanJohn RadfordJonathan E BrammerKatherin E CombsKirit M ArdeshnaKurt C GunterLihua E Budde
Issued Date
2021
Type
Article
Keyword
Epstein-Barr virusExtranodal NK/T-cell lymphomaImmunotherapyRelapsed and refractory.
DOI
10.1007/s00277-021-04558-0
URI
https://oak.ulsan.ac.kr/handle/2021.oak/8364
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_proquest_miscellaneous_2555350764&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Autologous%20EBV-specific%20T%20cell%20treatment%20results%20in%20sustained%20responses%20in%20patients%20with%20advanced%20extranodal%20NK%2FT%20lymphoma:%20results%20of%20a%20multicenter%20study&offset=0&pcAvailability=true
Publisher
ANNALS OF HEMATOLOGY
Location
미국
Language
영어
ISSN
0939-5555
Citation Volume
100
Citation Number
10
Citation Start Page
2529
Citation End Page
2539
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.